$2.21
2.21% yesterday
Nasdaq, Jun 13, 10:16 pm CET
ISIN
US8051111016
Symbol
SVRA
Sector
Industry

Savara, Inc. Stock price

$2.21
-0.76 25.59% 1M
-1.00 31.15% 6M
-0.86 28.01% YTD
-1.85 45.57% 1Y
-0.57 20.50% 5Y
-32.17 93.57% 10Y
-4,862.79 99.95% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.05 2.21%
ISIN
US8051111016
Symbol
SVRA
Sector
Industry

Key metrics

Market capitalization $381.97m
Enterprise Value $238.99m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.58
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-108.97m
Free Cash Flow (TTM) Free Cash Flow $-95.30m
Cash position $172.50m
EPS (TTM) EPS $-0.47
P/E forward negative
Short interest 12.60%
Show more

Is Savara, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Savara, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Savara, Inc. forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Savara, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Savara, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 29 29
60% 60%
-
- Research and Development Expense 80 80
54% 54%
-
-109 -109
56% 56%
-
- Depreciation and Amortization 0.13 0.13
30% 30%
-
EBIT (Operating Income) EBIT -109 -109
56% 56%
-
Net Profit -102 -102
59% 59%
-

In millions USD.

Don't miss a Thing! We will send you all news about Savara, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Savara, Inc. Stock News

Neutral
Accesswire
17 days ago
BOSTON, MA / ACCESS Newswire / May 28, 2025 / Block & Leviton is investigating Savara Inc. (Nasdaq:SVRA) for potential securities law violations. Investors who have lost money in their Savara Inc. investment should contact the firm to learn more about how they might recover those losses.
Neutral
GlobeNewsWire
18 days ago
ATLANTA, May 27, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) complied with federal securities laws. On May 27, 2025, Savara announced that it had received a refusal to file letter from the FDA for the Biologics License Application of MOLBREEVI as a therapy to treat patients with autoimmune pulmonary alveolar prote...
Neutral
GlobeNewsWire
18 days ago
Block & Leviton is investigating Savara Inc. (Nasdaq: SVRA) for potential securities law violations. Investors who lost money should contact the firm.
More Savara, Inc. News

Company Profile

Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.

Head office United States
CEO Matthew Pauls
Employees 59
Founded 1995
Website savarapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today